Deutsche Bank upgrades Schott Pharma on improved H2 outlook, shares rise

Deutsche Bank upgraded Schott Pharma to Buy from Hold and raised its price target to €22 from €16, citing expected growth acceleration in 2H 2026. The analyst noted 1H demand softness from a key glass syringe customer but expects growth to rebound in Q3–Q4 alongside improving margins, with full-year 2026 guidance achievable at the midpoint. Shares jumped over 8% early as the upgrade highlighted an “attractive” valuation versus Stevanato.

Analysis

This is more of a confidence-reset than a true industry re-rating: the key implication is that a prior customer-driven air pocket is likely temporary, so the market should start underwriting higher near-term volume leverage in a business where incremental revenue should fall through well. If the H2 recovery materializes, the bigger winner is not just the company in question but also upstream fill-finish and biologics packaging demand, because tighter syringe/vial supply can force customers to dual-source and rebuild inventory buffers.

The competitive read-through is bearish for premium multiple discipline in the sector. Stevanato’s valuation premium is vulnerable if a lower-multiple rival can show growth reacceleration plus margin expansion, because the market will question whether the premium is justified by scarcity or merely by better recent execution. That said, one customer is not a secular trend; if the slowdown was idiosyncratic, the move may be mostly a mean-reversion trade rather than evidence of broad packaging demand acceleration.

Catalyst timing matters: the next 1-3 months are about order commentary and whether Q3/Q4 actually inflects; the 6-18 month story depends on whether guidance for the next cycle proves achievable and whether margin expansion is sustained. The main falsifier is continued weakness in syringe demand or another guidance cut, which would indicate the issue is not transitory inventory digestion but a share-loss or end-market slowdown. In that case, the post-upgrade rally would likely fade quickly, especially if the stock moves ahead of the next print.

Contrarian view: the market may be underappreciating how much of the rerating is already in the start-of-day move, while still overrating the certainty of the second-half pickup. If the growth inflection is real, the cleaner trade is relative value versus the sector premium, not an outright chase after a one-day analyst revision. If access to the Frankfurt line is available, the asymmetry is better on a pullback than after an 8% gap-up.

Key Decisions for Investors

• If you have access to the Frankfurt listing, initiate a small long position in 1SXP on any post-upgrade pullback, using the next earnings/guidance update as the catalyst window; target a rerating toward the peer multiple if H2 growth inflects, with downside capped by the existing valuation discount.
• Fade Stevanato strength on rallies: reduce/short STVN as a relative-value hedge against a closing of the valuation gap, especially if Schott’s next quarter confirms margin recovery; thesis breaks if STVN re-accelerates materially faster than Schott on its own order book.
• Set an alert for the next quarterly release and guidance update: if Q3/Q4 growth does not accelerate and margin expansion is not visible, treat this as a dead-cat bounce and avoid adding risk to the long thesis.
• Monitor fill-finish and injectable supply-chain names for knock-on inventory restocking signals; a sustained uptick would support a longer-duration long in pharma packaging, while continued destocking would argue for no trade.
• No immediate US-listed expression is compelling enough to force a trade; if you need liquidity today, stay flat and wait for a better entry after the first follow-through reversal or confirmation print.